New Family Heart Foundation Study Finds Only 13% of Adults With Cardiovascular Disease Achieve Comprehensive LDL-C Management
The Family Heart Foundation, a leading research and advocacy organization, published new research in the American Journal of Preventive Cardiology revealing significant gaps in cholesterol management during 2022-23 among U.S. adults with atherosclerotic cardiovascular disease (ASCVD). Findings show that only 13% of adults with ASCVD were meeting three key components of optimal low-density lipoprotein-cholesterol (LDL-C) management, including receiving guideline-recommended therapy, consistently taking the therapy, and reaching an LDL-C level less than 70 mg/dL. According to the study, many factors contributed to this gap, including the low usage of non-statin therapies to treat LDL-C in high-risk patients. Based on the Family Heart Database® of 3.6 million individuals with ASCVD, the data showed:
